Scorpius Holdings Future Growth
Future criteria checks 2/6
Scorpius Holdings is forecast to grow earnings and revenue by 44.7% and 67.2% per annum respectively while EPS is expected to grow by 61.6% per annum.
Key information
44.7%
Earnings growth rate
61.6%
EPS growth rate
Biotechs earnings growth | 23.2% |
Revenue growth rate | 67.2% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 09 Oct 2023 |
Recent future growth updates
Recent updates
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Dec 28Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Sep 02Heat Biologics names Anthony Manning as chief scientific advisor
May 10Heat Biologics EPS misses by $0.01, misses on revenue
May 05We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely
Apr 30Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years
Mar 07Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Jan 13Heat Biologics signs a licensing agreement; Appoints new CFO
Jan 06Heat Biologics soars 14% on completion of ZVX-60 vaccine cell line for COVID-19
Dec 16Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year
Nov 20Heat Biologics Provides Update, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 35 | -17 | N/A | N/A | 1 |
12/31/2024 | 21 | -22 | N/A | N/A | 1 |
12/31/2023 | 7 | -40 | -34 | -32 | N/A |
9/30/2023 | 8 | -53 | -41 | -38 | N/A |
6/30/2023 | 8 | -55 | -44 | -26 | N/A |
3/31/2023 | 7 | -48 | -30 | -9 | N/A |
12/31/2022 | 6 | -43 | -26 | -6 | N/A |
9/30/2022 | 1 | -38 | -29 | -9 | N/A |
6/30/2022 | 1 | -36 | -30 | -29 | N/A |
3/31/2022 | 2 | -36 | -46 | -43 | N/A |
12/31/2021 | 2 | -35 | -40 | -38 | N/A |
9/30/2021 | 2 | -28 | -35 | -33 | N/A |
6/30/2021 | 2 | -29 | -27 | -23 | N/A |
3/31/2021 | 3 | -27 | -22 | -21 | N/A |
12/31/2020 | 3 | -26 | -22 | -22 | N/A |
9/30/2020 | 4 | -23 | -16 | -16 | N/A |
6/30/2020 | 4 | -20 | -15 | -15 | N/A |
3/31/2020 | 3 | -21 | -15 | -14 | N/A |
12/31/2019 | 3 | -20 | -13 | -13 | N/A |
9/30/2019 | 3 | -22 | -19 | -19 | N/A |
6/30/2019 | 5 | -19 | -18 | -18 | N/A |
3/31/2019 | 6 | -18 | -22 | -22 | N/A |
12/31/2018 | 6 | -16 | -22 | -22 | N/A |
9/30/2018 | 4 | -14 | -13 | -13 | N/A |
6/30/2018 | 3 | -13 | -13 | -13 | N/A |
3/31/2018 | 2 | -12 | -8 | -7 | N/A |
12/31/2017 | 2 | -12 | -6 | -6 | N/A |
9/30/2017 | 1 | -12 | N/A | -12 | N/A |
6/30/2017 | 1 | -11 | N/A | -10 | N/A |
3/31/2017 | 0 | -11 | N/A | -12 | N/A |
12/31/2016 | 0 | -13 | N/A | -14 | N/A |
9/30/2016 | 0 | -16 | N/A | -16 | N/A |
6/30/2016 | N/A | -19 | N/A | -18 | N/A |
3/31/2016 | N/A | -21 | N/A | -18 | N/A |
12/31/2015 | N/A | -20 | N/A | -17 | N/A |
9/30/2015 | N/A | -17 | N/A | -15 | N/A |
6/30/2015 | N/A | -15 | N/A | -14 | N/A |
3/31/2015 | N/A | -13 | N/A | -12 | N/A |
12/31/2014 | N/A | -12 | N/A | -10 | N/A |
9/30/2014 | N/A | -10 | N/A | -9 | N/A |
6/30/2014 | N/A | -10 | N/A | -9 | N/A |
3/31/2014 | N/A | -8 | N/A | -8 | N/A |
12/31/2013 | N/A | -9 | N/A | -6 | N/A |
9/30/2013 | N/A | -8 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SCPX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SCPX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SCPX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SCPX's revenue (67.2% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: SCPX's revenue (67.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SCPX's Return on Equity is forecast to be high in 3 years time